Inogen (NASDAQ:INGN) reported that the peer-reviewed journal, Pulmonary Therapy, has published a study demonstrating the association of portable oxygen concentrators with decreased mortality and increased cost-effectiveness ratio when compared to other long-term oxygen therapies.
The company reports that data was sourced from the French National Healthcare System database, SNDS, and included a sample size of more than 244,000 adult long-term oxygen therapy patients from 2013 to 2020, likely the largest retrospective claims database assessment study of long-term oxygen therapy to date. Results showed that portable oxygen concentrator (POC) use alone or in combination with other oxygen modalities, was associated with improved survival and lower related costs compared to stationary concentrators, compressed tanks, and liquid oxygen.
In a statement, Kevin Smith, president and CEO of Inogen, said that the company has long believed that mobile oxygen therapies, primarily portable oxygen concentrators, are associated with improved health outcomes, affordability, and patient quality of life. “We are proud that this study confirms the value proposition of our devices. Looking forward, we will continue to expand the adoption of our effective and high-quality POCs, enabling more patients to experience these benefits.”
Inogen is a leading global medical technology company developing, manufacturing, and marketing innovative respiratory products for homecare use.
